Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
clinical trial
|
| gptkbp:analyzes |
gptkb:Dr._Smith
gptkb:Dr._Johnson |
| gptkbp:approves |
gptkb:Institutional_Review_Board
|
| gptkbp:built |
2018-12-31
|
| gptkbp:clinicalTrials |
ClinicalTrials.gov
highly significant results |
| gptkbp:collaborations |
gptkb:Johns_Hopkins_University
gptkb:University_of_California |
| gptkbp:collection |
prospective
|
| gptkbp:condition |
breast cancer
|
| gptkbp:criteria |
previous chemotherapy
histologically confirmed breast cancer |
| gptkbp:dataTransmission |
available upon request
|
| gptkbp:dosageForm |
gptkb:TAC_regimen
AC regimen |
| gptkbp:drugInterdiction |
doxorubicin
cyclophosphamide |
| gptkbp:duration |
2 years
|
| gptkbp:enrollment |
diverse backgrounds
200 participants female patients age 18-65 |
| gptkbp:funding |
government funded
|
| gptkbp:future_plans |
Phase II
|
| gptkbp:healthcare |
informed consent required
|
| https://www.w3.org/2000/01/rdf-schema#label |
PROMISE-2
|
| gptkbp:is_a_source_of |
treatment
|
| gptkbp:is_monitored_by |
serious adverse events
|
| gptkbp:is_studied_in |
small sample size
randomized controlled trial short follow-up period interventional treatment phase |
| gptkbp:launchDate |
2015-01-01
|
| gptkbp:lighting |
single-blind
|
| gptkbp:location |
gptkb:United_States
|
| gptkbp:matchType |
adult patients
|
| gptkbp:notableWork |
further studies needed.
|
| gptkbp:outcome |
overall survival
positive impact on treatment guidelines |
| gptkbp:primaryMission |
response rate
|
| gptkbp:publicationDate |
2019-03-01
|
| gptkbp:publications |
gptkb:Journal_of_Clinical_Oncology
|
| gptkbp:recognizes |
NCT02345678
|
| gptkbp:result |
2019-01-15
improved survival rates published in medical journal reduced recurrence rates |
| gptkbp:safetyFeatures |
chemotherapy
|
| gptkbp:secondaryMission |
quality of life
|
| gptkbp:sponsor |
gptkb:National_Cancer_Institute
|
| gptkbp:technique |
statistical significance
computer-generated random numbers |
| gptkbp:technology |
long-term effects
combination therapies |